TONIX PHARMACEUTICALS HOLDING CORP. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.96 per share for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2021-08-09
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-06-30 was $0.96, a 41.18% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-06-30 was $0.68.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $0.35, a 97.75% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $15.55.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $16.54, a 94.05% decline from fiscal 2018.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $277.77.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2012 was $1.18.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2021-06-30 | $0.96 10-Q · filed 2021-08-09 | $1.08 10-Q · filed 2021-08-09 | |||
| 2020-09-30 | $0.66 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $0.68 10-Q · filed 2021-08-09 | $0.66 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $0.35 10-Q · filed 2020-05-12 | ||||
| 2019-12-31 | $16.54 10-K · filed 2020-03-24 | ||||
| 2019-09-30 | $16.54 10-Q · filed 2020-11-09 | ||||
| 2019-03-31 | $15.55 10-Q · filed 2020-05-12 | ||||
| 2018-12-31 | $277.77 10-K · filed 2020-03-24 | ||||
| 2016-03-31 | $1.53 10-Q · filed 2016-05-06 | ||||
| 2015-03-31 | $6.24 10-Q · filed 2015-05-08 | ||||
| 2012-12-31 | $1.18 10-K · filed 2013-03-11 | ||||
| 2012-09-30 | $1.18 10-Q · filed 2012-11-14 | ||||
| 2012-06-30 | $1.18 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |